Radiation-Protective Agents

• 

  Subject Areas on Research

  • A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. 
  • A manganese porphyrin superoxide dismutase mimetic enhances tumor radioresponsiveness. 
  • A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. 
  • Amifostine as a radioprotectant. 
  • Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). 
  • Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. 
  • Are We Ready for a Radiological Terrorist Attack Yet? Report From the Centers for Medical Countermeasures Against Radiation Network. 
  • Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). 
  • Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity. 
  • CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. 
  • Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. 
  • Chloroquine improves survival and hematopoietic recovery after lethal low-dose-rate radiation. 
  • Clarifying the Relative Impacts of Vascular and Nerve Injury That Culminate in Erectile Dysfunction in a Pilot Study Using a Rat Model of Prostate Irradiation and a Thrombopoietin Mimetic. 
  • Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. 
  • Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. 
  • Cytoprotection for radiation-associated normal tissue injury. 
  • Does amifostine have a role in chemoradiation treatment? 
  • Early and late administration of MnTE-2-PyP5+ in mitigation and treatment of radiation-induced lung damage. 
  • Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation. 
  • Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. 
  • Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 
  • Ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin. 
  • Future directions in toxicity prevention. 
  • Future directions in toxicity prevention. 
  • Has the outlook improved for amifostine as a clinical radioprotector. 
  • Influence of WR 2721 on radiation response of canine soft tissue sarcomas. 
  • Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. 
  • Inhibition of the Continuum of Radiation-Induced Normal Tissue Injury by a Redox-Active Mn Porphyrin. 
  • Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. 
  • MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. 
  • Metalloporphyrin antioxidants ameliorate normal tissue radiation damage in rat brain. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Modulation of ultraviolet light-induced epidermal damage: beneficial effects of tocopherol. 
  • Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model. 
  • Pharmacologic approaches to radiation protection. 
  • Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. 
  • Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. 
  • Prevention and treatment of sunburn. 
  • Proteomic analysis of radiation-induced changes in rat lung: Modulation by the superoxide dismutase mimetic MnTE-2-PyP(5+). 
  • Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. 
  • Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. 
  • Radioprotection of lipogenesis from glucose (U-14C) and activities of pyridine nucleotide dehydrogenases in liver of gamma-irradiated female rats by cystamine. 
  • Radioprotection of liver lipids of whole-body gamma-irradiated female rats by cystamine. 
  • Radioprotection of lungs by amifostine is associated with reduction in profibrogenic cytokine activity. 
  • Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+. 
  • Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents. 
  • Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxia-telangiectasia cells. 
  • Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP(5+). 
  • Spleen lipids: effect of whole body gamma irradiation and radioprotective chemicals. 
  • Strategies for optimizing the response of cancer and normal tissues to radiation. 
  • Superoxide dismutase mimic, MnTE-2-PyP(5+) ameliorates acute and chronic proctitis following focal proton irradiation of the rat rectum. 
  • The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome. 
  • The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation. 
  • The protective effect of recombinant human keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. 
  • The role of amifostine as a radioprotector. 
  • Thioredoxin mitigates radiation-induced hematopoietic stem cell injury in mice. 
  • Toxicity, biodistribution and radioprotective capacity of L-homocysteine thiolactone in CNS tissues and tumors in rodents: comparison with prior results with phosphorothioates. 
  • Ubiquinone, idebenone, and kinetin provide ineffective photoprotection to skin when compared to a topical antioxidant combination of vitamins C and E with ferulic acid. 
  • Utilizing Superoxide Dismutase Mimetics to Enhance Radiation Therapy Response While Protecting Normal Tissues. 
• 

  Keywords of People

  • Warner, David Samuel, Distinguished Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology